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Chapter l0
I .  INTRODUCTION
Cancer is a disease caused by the accurnu-
lation of multiple genetic aberrations in a
cel l ,  f ina l ly  leading to uncontro l led cel l
growth and metastasis. Due to these mul-
tiple genetic aberrations, e.g. chrolnosolnal
deletions, duplications and translocations
and genc lnutations. cancer is a vcry corn-
plex disease. If no appropriate therapy can
be given, cancer will eventually lead to death
ofthe inflicted patient. However, the genetic
rnalfonnations cause the tumor cell to dif-
fer frorn the surrounding nonnal cclls and
this difference can be used to develop tu-
rnor specific therapy. It appears that each
type of tun.ror has in addition to general ab-
errations found in all cancers also specific
genetic aberrations causing certain genes to
be either expressed or deleted. lf tl.re over-
expression or deletion of a gene promotes
cell growth the gene is defined as an onco-
gene or turnor suppressor gcne" respectively.
Lung cancer is characterized by the inacti-
vation of the tumor suppressor gcnes p53
and RB, mutation in the oncogenes Ras and
Myc, the overexprcssion of thc apop-tosis-
sensitivity rnediating ene Bc12 and allelic
losses of chrolnosoÍre 3o. In this thesis two
genes were studied, the epithelial glycopro-
tein-2 (EGP-2) gene and the ubi-quitin-ac-
tivating enzyrne E I like (UBE I L) gene, both
of  which have an aberrant  expression pat-
tern in small cell lung carcinornas (SCLC).
SCLCs al rnost  a lways show overexprcssiorr
o f  EGP-2  and  reduced  exp ress ion  o f
UBEI L. The latter is located at chrornosorre
3p21 .3,  a region consistent ly  deleted in
SCLC. The first part of the thesis focuses
on EGP-2 and its r-rse as target to direct car-
cinorna-specific therapy, whereas thc sec-
ond part of the thesis focuses on UBE I L in
relation to SCLC. A general introduction to
EGP-2 and UBEIL is  g iven inchapter  l .
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2. PART I EGP-2
EGP-2 is expressed as a 38 kDa transrnern-
brane glycoprotein, not only on small cell
lung carcinornas but also on ahnost all car-
cinornas and is therefore considered to be a
very attractive tumor associated antigen
(TAA). Because of this, EGP-2 can be used
as a target for carcinorna-specific therapy.
This includcs imrnunotherapy using EGP-2
as a vaccine, by loading iurmune effector
cells with EGP-2-derivcd peptides, or by
using antibodies pecific for EGP-2 or modi-
fied derivatives hercof. Ovcr the last l0-
years several tl.rerapies using monoclonal
antibodies (Mab) directed against EGP-2
havc entered thc clinic, howevcr, with dis-
appointing results regarding their effrcacy
and safety. Only in cases of minin.ral residual
disease anti-EGP-2 Mab therapy seerns uc-
cessful. Severe toxicity has been reported
to accompany this trcatment, however. This
treatrnent-re lated toxicity may be caused by
cnhanced imrnune system reactions or by
the infliction of darnage to EGP-2-express-
ing normal epithelial t issues. Besides on the
surface of rnost carcinorna cells, EGP-2 is
also expressed on normal sirnple epithelial
cells. E,GP-2 on norural cells appears to be
shielded frorn the circulation by the base-
rnent mcrnbranc. To study the in vi vo effect
of TAA-directed irnrnunotherapy on norrnal
tissue accurately, rnore relevant animal rnod-
c ls  are needed.  By thc developrnent  of
transgenisis it has becorne possible to gen-
erate anirnals that express human genes in a
way that is identical to hurnans.
ln chapter 2 ofthis thesis the relevance
of transgenic animal models to study anti-
tumor irnmunotherapy is discussed. In or-
der to do so, transgenic animal n.rodels that
have been described to date in the literature
were divided into four groups; i.e. animals
cxpressing hurnan TSA or  TAA, HLA,
oncogene, and irnmune effector molecules.
Each of these are of particr-rlar interest to a
specific immunothcrapeutical approach.
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Results obtaincd witl i  these nricc have al-
ready been extrapolated to the hunran situ-
ation, as thesc approaches are currcntly be-
ing flrrthcr cvaluatcd in clinical scttings.
[{owcvcr, obscrved contradictory rcsults,
strain dcpcndcnl effects, and cii l- lèrences
between rnicc and rnarl, ernphasizc the need
to intclprct rcsults obtaincd in animal mod-
c ls  wi th caut ion.  Ncver thelcss,  g ivcn the
Inany constraints in sctting-up human clini-
cal trials, transgcnic lnicc arc uscÍirl prcclini-
c r l  sys t cn l s  l i r l  e i  l l r r a l i r t g  l r r r t i cn r t ce r  i r n -
n.r.rnothcrapcutica I strategics.
Dcspi tc  t l rc  l r r r rnelous l r l rnsgcrr ic  rn i -
mals gcllcratccl, no EGP-2-tlansgcnic ani-
mal was rcpurtcd that accr-rratcly cxpfcsses
thc EGP-2 gcnc thus far. ThercÍirrc, wc de-
cidcd to gcncratc i i lr EGP-2-transgcnic ani-
rnal trLmor'-rrroclcl to study anti-lrGP-2 di-
rected N1ab nrcdiated in . rnrurrotherapy.
Since, our rcscarch group hacl previously
dcvcloped a ra1 turnor modcl in which anti-
EGP-2 Mab thcrapy could bc studicd suc-
cesstully. it rvas dccidecl init ially to scner-
atc an EGP-2-transgcnic rat.
In chaptcr 3 the gcncration and char-
actcrization ol'thc EGP-2-cxprcssirrg trans-
genic rat turnor-rnodel is prcscntcd. ln this
rat EGP-2 cDNA cxpression is clircctcd by
the keratin I 8 (Kl l l) f lanking scclucnces. hr
this EGP-2 transgcnic rat EGP-2 proved to
be expressecl on thc surÍace ofthc cxo- and
cnclocrine cclls ofthc pancreas and on the
surface of thc lrcpatocytes and bilc dLrcts in
t h c  l i v e r .  U p o n  b a c k c r o s s i n g  o f  t h e
transgenic Wistar  rat  wi th an L37-tunror
co rnpa t i b l c  \ \ ' ag ,R i j  r a t ,  an  EGP-2 -
transgenic rat tun.rclr-rnodel was cstabl i shed.
In this E(iP-2-tlansgenic rat tuuror-nrodel
the localization properlies of thc anti-EGP-
2 Mab MOC'3 I  was evaluatcc l .  In t rave-
nous l y  app l i cd  MOC3 I  l oca l i zcc l  t o  t he
EGP-2-posi t ivc t r .nror  and thc l ivcr  but  not
to thc EGP-2-ncgative turnor antl the pan-
crcas, indicating that thc EGP-2 cxprcssion
in the pancrcas, but not in thc l ivcr, of thc
EGP-2 trausgcnic rat is shicldccl iom the
ci rculat ion,  probably by the basal  rncrn-
branc, as has been obscrved for EGP-2-posi-
tivc tissues in hur.nans. Thereforc. this ani-
rnal moclel is only partly suitable fbr the
eva lua t i on  o f  an t i - l lGP-2  d i rec ted  Mab
basccl i lnurunotherapy strategies. To gcncr-
atc EGP-2 transgenic aniurals witl i  an tiGP-
2 cxprcssior.r pattern sirnilar to the EGP-2
exprcssion pattem in humans we isolatcd tlre
EGP-2 genornic sequcnces including its 5'
and 3' rcgulatory scclr"rcnces and stuclicd
thcsc both in vítto ancl r yrlo.
In chapter 4 upstrciim EGP-2 regula-
tory scquences (3.6 kb) rvcre assessed Íur
thcir abil ity to convey cpitheliurn, and thcrc-
Íirrc also carcinorna. spccificity to hetcrolo-
gous gcues.  Analys is  of  the expression of
constn lc ts  carry ing thc EGP-2 cDNA. thc
cnhanccd grcen fluclrcsccnt proteir.r (EGFP)
ancl  luc i fcrasc gcucs,  and t l . re  cytos inc
clcanrinasc (CD) suicidc gcnc under control
of thc EGP-2 prornotcr, showed that exprcs-
sion of the heterologous gelres was indccd
restr ic tcc l  to  cel l  l incs cxpressing EGP-2.
Dclction analysis clcfinccl 687 bp upstrcaur
as thc basic  prox inra l  pro lnoter  region,
which can confer cpithcliun'r-speciÍlc cx-
prcssion in vitro. As thcsc EGP-2 scqucnccs
can cunÍ-cr prornoter activity to suicide gcncs
l ikc ( 'D in  a t issue spcci Í ic  manner they can
be usccl to enhance thc specificity in carci-
rrorna-clirected suicidc gcne therapy.
In chapter  5 a tota l  o f  55 kb of  I rGP-
2-gcnonric sequences includir.rg the l4 kb
genour ic  EGP-2 genc,  l  0  kb of5 'sequenccs
and 3 I kb of3' sequcrrccs. were used to gcn-
eralc an EGP-2-transgcr.ric rnouse. In thc trvo
EGP-2-transgenic Íirunder Iines gcncratccl,
EGP-2 was exprcsscd specil ically in all cpi-
thc l ia l  t issues,  para l lc l  to  t l re  expression of
EGP-2 in human.  whcrcas a l l  o ther  t issLrcs
wcrc ncgat ive.  Upon backcrossing of  thc
L,Ci P-2 -transgenic r.r.rt'rusc F V BN stra in lv i th
thc B ló- turnor  compat ib lc  C57i  BL6 st ra in,
ECiP-2-positive ancl -ncgativc Bl6 tumors
could bc induced. Subscclucntly, ocal ization
of  thc ant i -EGP-2 Mab MOC3 I  was cva-
r69
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luated in this EGP-2-transgenic Inouse tu-
rnor-model. Intravenously applied MOC3 I
localized to the EGP-2-positive tumor and
not to the EGP-2-negative turnor. hnpor-
tantly, no anti-EGP-2 Mab localization was
observed in any of the EGP-2-positive nor-
rnal mouse tissues indicating lirnitediru vi vo
acccssibil i ty. This EGP-2-transgenic mouse
rnodel rnay be instrunental to a better un-
derstanding of the function of EGP-2 in de-
veloprnent, maintenance, and turnorigenisis
of ep-ithelial tissues and rnay be a useful
tool for thc development and evaluation of
theraper.rtic strategies cmploying EGP-2 as
target
3.  PART I I  UBEIL
Allelic losses in human lung cancer occur
rnost consistently in the 3p2 I region. The
u b i q u i t i n - a c t i v a t i n g  e n z y m e  E 1  l i k e
(UBEI L) gene located in this region is well
expressed in normal adult lung but was
found to be expressed at greatly reduced
levels in small cell lung cancer, as assessed
by Norlhern blot and RT-PCR analysis. The
reduced expression of UBEIL mRNA in
hurnan lurrg cancer is  in t r igu ing.  s ince usu-
ally one of the two copies remains. To fur-
thcr characterize the protein product, we
generated UBE lL protein-specific antibod-
ies.
ln  chapter  6 the developrnent  of  a
monoclonal and a polyclonal antibody rec-
ognizing the UBE I L protein is described. A
pur i f icd E.co l i -expressed recombiuant
UBEIL plotein Íiagrnent and an UBEIL
sequencc-deduced synthetic oligopcptide
coupled to KLH were used to generate
UBEl L-specific antibodies. Iumunoblot
analysis with these antibodies revealed a
full-length UBEI L gene product of approxi-
rnately 112 kDa, present in normal cells and
non-lung cancer cells but absent in all as-
sessed human small cell h:ng cancer cell
lines, confinning the data obtained from the
110
expression analysis at the rnRNA level. [r.n-
rnunohistocl'remical analysis showed that the
UBElL protein was rnostly present in the
cytoplasrn. This localization is in contrast
to what is known from its putative look-a-
like, the well known UBEl, which shuttles
in a cell cycle-dependent way between the
nucleus and the cytoplasrn. To assess a pos-
sible role of UBEIL in lung cancer devel-
opment, we reintroduced UBEI L expression
into a small cell lung cancer-derived cell
linc. However, no apparent alterations in the
cancer cell phenotype were observed upon
stable transfection of the UB E I L genc in this
cel l  l ine.
Analysis of the remaining UBE lL copy
in lung cancer d id not  show mutat ions.
Thercfore, a regulatory block ofexpression,
due to loss offunction ofa transcription fac-
tor or deletion of the prornoter region could
be responsible for the observed reduced lev-
els of UBE lL expression in lung cancer. Pre-
v ious analys is  of  1.28 kb of  UBEIL up-
strearn sequenccs showed that demethy-
lation of the upstreanr region of the gene
did not enhance UBE lL rnRNA expression.
Fufthennore, it was sl.rown that this region
contained two DNase I hypersensitivity
sites. Therefore, we decided to isolate an
additional 3 kb of UBEIL upstreatn se-
quences covering the second hypersensitiv-
ity site.
In chapter 7 the structure and charac-
terization of the human UBEIL prornoter
and the analyscs of  cr .s-act ing sequences
needed for expression ofheterologous genes
in lung cancer-derived cell l ines are pre-
sented. It was shown that the basic promoter
covered a region of-154 bp upstrearn from
the initial start site, that the actual start site
was lnost l ikely located -17 bp r-rpstrearn of
this init ial starl site. In addition the UBEIL
prornoter activity seems at lcast regulated
by binding of transcription factors to an lnr
and an Ets-l consensus elernent. However"
no significant differences in the regulation
of  up to 4.3 kb of  UBEIL upstrearn se-
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octed upon transfection
of these sequences and a reporter gene in
UBElL expressing and non-expressing
srnall cell lung canccr-derived cell l ines.
This irnplicates that the observed down
regulation of UBE I L in small cell lung can-
cer is regulatcd at a different level. To in-
vestigate the UBE I L promoter regulation ir
yivr.r, wc created transgcnic rnouse lines con-
ta in ing the 4.3 kb UBEIL prornoter  se-
quence fused to the EGFP reporter gene.
Four transgcnic foundcr l ines were gencr-
atcd eacl.r canying copies of the transgene
intcgratcd at a diíïerent position in the chro-
rÍlosolncs. Although EGFP expression could
bc detccted in thcse UBEIL-EGFP trans-
genic rnice, the UBEI L prornoter region was
not sulïcient to drive EGFP expression in a
distribLrtion pattern similar to that of human
UBEl L. In addition, the UBEI L prornotcr-
driven EGFP cxpression was too low to al-
low dircct f lourornetric detection of EGFP
by fluoresccnt rnicroscopy. These latter fea-
tures combined with thc above described in
viíro data indicatc the possible involvemcnt
ofyet another egulatory elernent such as a
locus control region (LCR) in the regula-
tion of UBEIL expression both in nonnal
cc l ls  and in SCLC.
Sequence analysis at the amino acid
level, showed a 45%u homology of UBE lL
to the ubiqui t in-act ivat ing er . rzyrne El
(UBEI ), a key enzyrre in thc ubiquitin sys-
tern, operative in a variety of eukaryotic ell
funct ions.  The sequence s i rn i lar i t ies be-
twcen UBEI and UBEIL include identical
sequences Íbr the ATP binding site GAG
AIG and the active-site Cyteines rcsidue,
which becornes l inked to ubiquitin in an E l-
Ub thiocster. Recently, new ubiquitin-l ike
protein modification pathways following the
salne enzyrnatic principles of activation,
conjugation and ligation as the ubiqr.rit in
protein modification pathway havc becn
discovered. Despite sequence differences
betwecn UBEI,  UBE lL and the scquences
of the newly discovercd Nedd8 and Sentrin
activating cnzyrnes they all contain a con-
served ATP binding site and active cysteine
residue. Thercfore, the UBE I L gene rnight
have a funct ion as an act ivat ing enzyrne in
a sti l l  unknown ubiquitin-l ike rnodification
pathway. A way to study the function of a
gene is to delete the gene of interest nanín
vlvo model, such as the rnouse, by generat-
ing a so-called knockout lnouse. The first
step towards the generation of a knockout
lnouse is the isolation and characterization
of the mouse homologr.rc of the gene of in-
tcrest.
Chapter 8 describes thc isolation and
characterization of the rnouse UBEIL ho-
rnologue Ube l l .  The genornic  organizat ion
of the Ubell gcne is very sirnilar to the ge-
nomic organizat ion of  the UBEIL gene.
Also its chrornosornal location is sirnilar.
since the Ubellgene is located at chrorno-
some 9 band F, a region known to be ho-
rnologor.rs to the hurnan 3p2l .3 region. The
latte r irnplies that the dr.rplication of Xp I 1.3-
11.23,  the region where UBEI is  s i tcd,  to
chrornosome 3p21 .3,  the region wherc
UBE I L rcsides. as described for hurnans is
an early event wl.rich took place in a mutual
human and mouse anccstor. The rnousc ho-
mologue of UBEI L has the same conscrved
sequcnce similarit ies at the UBE l-hornolo-
gous act ivat ion dourain suggest ing a s imi-
lar function as the UBE I L gene. This is sup-
ported by the fact that the Ube I I expression
pattcrn as detemined by RT-PCR only
slightly deviates frorn the UBEIL cxpres-
sion pattcm as determined by imrnunoblot-
ting in chapter 6. Howeveq an UBE.I L ftlnc-
tion has not been established yet and a pos-
sible rolc in lung cance r devcloprnent is un-
certain. Atternpts cuffently in progress to
construct a mouse rnodel deficient Íbr Ube I I
by targcted inactivatior-r of Ubell should
provide better understanding ofthe function
of UBEIL and its role in lung cancer.
Because ofits consistently reduced ex-
pression in lung cancer, UBEIL rnight rep-
resent a class I turnor suppressor, i.e. one
which is inactivated by (functional) loss of
t l l
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both gene copies. Howeveq reintroduction
of UBEI L into cancer cell lines did not re-
duce the turnorigenicity of the cell lines.
This would still leave open a possible role
of UBEIL in the developrnent of lung can-
cer  as a c lass I I  lurnor  suppressor  gene" i .c .
by loss ofone copy and a regulatory block
of the other. The knockout mouse rnodel
currently being generated, as mentioned
above, might give more infonnation con-
ceming the role of UBEIL in lung cancer.
Since the generation of the first knockout,
in 1987, a number of tumor-suppressor
knockout trrouse models have been gener-
ated. However, these knockout mice of tu-
mor suppressor genes vary in the degree in
which they can bc used as a model for the
human situation.
In chapter 9 the tumor-suppressor
knockout mouse models generated to date
are discussed based on their phenotypic re-
semblance to the hun,an situation. lt turned
out that approxirnately 50% of the gener-
ated tumor suppressor knockout-mice mod-
els closely reflect the human syndrome. The
development of second generation gene-tar-
geting technologies as briefly outlined in
chapter I and the generation of double
knockout rnice will probably increase the
number of mice models closely reflecting
the human situation in the near future.
4.  GENERALDISCUSSIONAND
FUTURE PERSPECTIVES
Lung cancer is in principal a genetic dis-
ease wi lh  genel ic  mal format ions occuming
during the somatic cellular phase. Starting
from this point of view, lung cancer specific
therapies can take the genetic malformations
specific for lung cancer, as targeting points
for therapy application. The two distinct
genes dealt with in this thesis, the epithelial
glycoprotein-2 (EGP-2) and the ubiquitin-
activating enzyme El l ike (UBEIL) genes,
show an aberrant expression in lung can-
112
cer; e.i. EGP-2 is overexpressed, whereas
the UBElL exprcssion is strongly reduced.
Because of  i ts  overcxpression in  carc inornas
EGP-2 serves currently as a target for can-
cer diagnosis and for experirnental anti-can-
cer immunotherapy. The latter, however,
with only limited success until now. To re-
fine the current anti-EGP-2-based treatment
st rategies,  re levant  animal  models are
needed. To this end, both EGP-2-transgenic
animal models described here are useful.
However,  s ince,  the EGP-2- t ransgenic
mouse model shows a more accurate resem-
blance to the expression of EGP-2 seen in
humans, it is more l ikely that unwanted
treatment-associated side-effects wil l be
detected in  lh is  EGP-2- t ransgenic rnouse
tumor model. A disadvantage of both mod-
els is, however, the artificial way of estab-
lishing tumors in these animals. By cross-
ing the EGP-2-transgenic animals with ani-
mals developing spontaneous fumors; e.g.
anirnals expressing lung cancer specific an
oncogene in the near future an even more
accurate E,GP-2-transgenic animal tumor
model can be generated. In that case the ef-
ficacy and safety of anti-EGP-2 therapy can
be studied in all stages of disease. Since,
transgenic rats are rare and a large variety
of transgenic mice are available to date, this
approach will initially be only easy to fol-
low for the EGP-2transgenic mouse rnodel.
An alternative for the treatment of can-
cer besides standard therapy is gene therapy.
Among the different approaches suicide
gene therapy, which consists ofthe transfer
of a suicide gene into the cancer cell fol-
lowed by the corresponding prodrug treat-
ment, is one of the most promising. How-
ever, here the specificity ofthe therapy for
the tumor cell is of great importance. To this
end, the observed carcinoma specificity of
the EGP-2 promoter seems very suitable to
direct the expression of prodrug converting
enzymes to carcinoma cells only. However,
in vivo specificity of the EGP-2 promoter
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the EGP-2 promoter
has not yet been demonstrated. By generat-
ing transgenic animals expressing heterolo-
gous genes under control ofthe EGP-2 pro-
moter this will be investigated in the near
future.
Another gene therapeutical approach is
to induce expression ofa therapeutic gene
in target tissue to correct aberrant genomic
function. Therefore, therapeutic genes, such
as tumor suppressor and anti-oncogenes,
must first be identified. In search of a lung
cancer specific tumor suppressor gene,
which should be located at chromosome
3p2l .3, over thirty genes have been identi-
fied with aberrant expression in lung can-
cer, among which the UBEIL gene. Studies
on the regulation of UBEIL as described in
this thesis suggest that the observed aber-
rant expression of this and probably also
other genes located in this region, is caused
by a disregulated transcription, provokedby
regulatory elements such as locus control
regions (LCRs). More proof about the in-
volvement of a regulatory element such as
an LCR in the regulation of UBEIL and
other genes located at 3p213 can be ob-
tained by generating transgenic mice with
band 3p2 1.3 and analyzing the dependency
of UBEIL and neighboring genes expres-
sion in these mice on the site of integration.
Despite numerous improvements, the
overall outcome from standard treatments
for lung cancer remains poor. Therefore,
innovative techniques must be developed to
enhance current forms of therapy. At the fore
front of anti-cancer experimental medicine
are immuno-and gene-therapy. However,
although the number of reports document-
ing successful immuno- and gene-therapy
increases, there is clearly a need to enhance
our knowledge oflung cancer and to evalu-
ate existing and novel immuno- and gene-
therapeutical strategies. The transgenic ani-
mal models and in vitro studies presented
in this thesis provide a small step in this di-
rection.
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